Immunocore
IPOPioneers of the world's first approved TCR therapy
- Business Model
- B2B
- Website
- immunocore.com
- Type
- Public
About
Immunocore is a commercial-stage biotechnology company that discovered, developed, and commercialized the world's first approved T cell receptor (TCR) therapy, built on its proprietary ImmTAX platform derived from University of Oxford research. The modular platform underpins a pipeline of bispecific immunotherapies spanning oncology, HIV, and HBV, plus autoimmune disease, with partnerships including Genentech, GSK, and the Bill & Melinda Gates Foundation.
Summary
Immunocore is a Healthcare company.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...
BridgeBio makes targeted treatments for genetic diseases.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...